Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study.

MLA

Hiromichi Matsuoka, et al. “Study Protocol for a Multi-Institutional, Randomised, Double-Blinded, Placebo-Controlled Phase III Trial Investigating Additive Efficacy of Duloxetine for Neuropathic Cancer Pain Refractory to Opioids and Gabapentinoids: The DIRECT Study.” BMJ Open, vol. 7, no. 8, Aug. 2017, pp. 1–8. EBSCOhost, https://doi.org/10.1136/bmjopen-2017-017280.

APA

Hiromichi Matsuoka, Hiroto Ishiki, Satoru Iwase, Atsuko Koyama, Takashi Kawaguchi, Yoshiyuki Kizawa, Tatsuya Morita, Yoshinobu Matsuda, Tempei Miyaji, Keisuke Ariyoshi, & Takuhiro Yamaguchi. (2017). Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study. BMJ Open, 7(8), 1–8. https://doi.org/10.1136/bmjopen-2017-017280

Chicago

Hiromichi Matsuoka, Hiroto Ishiki, Satoru Iwase, Atsuko Koyama, Takashi Kawaguchi, Yoshiyuki Kizawa, Tatsuya Morita, et al. 2017. “Study Protocol for a Multi-Institutional, Randomised, Double-Blinded, Placebo-Controlled Phase III Trial Investigating Additive Efficacy of Duloxetine for Neuropathic Cancer Pain Refractory to Opioids and Gabapentinoids: The DIRECT Study.” BMJ Open 7 (8): 1–8. doi:10.1136/bmjopen-2017-017280.